{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T22:25:39Z","timestamp":1761171939227,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.farma.2023.06.007","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T23:28:36Z","timestamp":1690241316000},"page":"T183-T189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["[Translated article] Have changes concerning carboplatin and anthracyclines been incorporated?"],"prefix":"10.1016","volume":"47","author":[{"given":"Susana Redondo","family":"Capafons","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Soriano","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsa Dalmau","family":"Portulas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c0lex Barrag\u00e1n","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio Mart\u00ednez","family":"Robles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f2nica","family":"G\u00f3mez-Valent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"Palumbo","key":"10.1016\/j.farma.2023.06.007_bb0005"},{"key":"10.1016\/j.farma.2023.06.007_bb0010","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2217\/fon-2018-0872","article-title":"Preventing chemotherapy-induced nausea and vomiting with netupitant\/palonosetron, the \ufb01rst \ufb01xed combina-tion antiemetic: current and future perspective","volume":"15","author":"Aapro","year":"2019","journal-title":"Future Oncol"},{"issue":"supl 3","key":"10.1016\/j.farma.2023.06.007_bb0015","first-page":"117","article-title":"Tratamiento de la \u00e9mesis inducida por quimioterapia","volume":"27","author":"Vera","year":"2004","journal-title":"Anales Sis San Navarra"},{"author":"Roila","key":"10.1016\/j.farma.2023.06.007_bb0020"},{"key":"10.1016\/j.farma.2023.06.007_bb0025","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","article-title":"The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"28","author":"Dranitsaris","year":"2017","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1016\/j.farma.2023.06.007_bb0030","first-page":"271","article-title":"Updated MASCC\/ESMO consensus recommendations: Emetic risk classi\ufb01cation and evaluation of the emetogenicity of antineoplastic agents","volume":"2017","author":"Jordan","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.farma.2023.06.007_bb0035","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/annonc\/mdx120","article-title":"Identifying predictive factors of chemotherapy-induced nausea and vomiting (CINV): a novel approach","volume":"28","author":"Scott\u00e9","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.farma.2023.06.007_bb0040","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1056\/NEJMra1515442","article-title":"Profilaxis antiem\u00e9tica para n\u00e1useas y v\u00f3mitos inducidos por quimioterapia","volume":"374","author":"Navari","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.farma.2023.06.007_bb0045","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/107815529900500303","article-title":"Antiemetic guidelines: A cooperation between a non-university hospital (Klinikum Remscheid) and a university center (Medical University of L\u00fcbeck) in Germany","volume":"5","author":"Junker","year":"1999","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.farma.2023.06.007_bb0055","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/annonc\/mdl137","article-title":"A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy","volume":"17","author":"Aapro","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.farma.2023.06.007_bb0060","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(08)70313-9","article-title":"Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomized, comparative phase III trial","volume":"10","author":"Saito","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.farma.2023.06.007_bb0065","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/annonc\/mdg417","article-title":"Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind random-ized phase III trial comparing single doses of palonosetron with ondansetron","volume":"14","author":"Gralla","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.farma.2023.06.007_bb0070","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/annonc\/mdu110","article-title":"Ef\ufb01cacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemo-therapy: a randomized dose-ranging pivotal study","volume":"25","author":"Hesketh","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.farma.2023.06.007_bb0075","series-title":"Antiemesis","article-title":"NCCN clinical practice guidelines (NCCN Guidelines\u00ae)","author":"National Comprehensive Cancer Network (NCCN)","year":"2020"},{"author":"Heshketh","key":"10.1016\/j.farma.2023.06.007_bb0080"},{"key":"10.1016\/j.farma.2023.06.007_bb0085","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/annonc\/mds021","article-title":"The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)","volume":"23","author":"Aapro","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.farma.2023.06.007_bb0095","doi-asserted-by":"crossref","DOI":"10.1007\/s12094-021-02623-8","article-title":"Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain","author":"Escobar Alvarez","year":"2021","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"10.1016\/j.farma.2023.06.007_bb0100","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1078155214524809","article-title":"Adherence to antiemetic guidelines and control of chemotherapy-induced nausea and vomiting (CINV) in a large hospital","volume":"21","author":"Caracuel","year":"2015","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.farma.2023.06.007_bb0105","first-page":"144","article-title":"Herreros de Tejada A.Variabilidad de las pautas antiem\u00e9ticas en un hospital oncol\u00f3gico","volume":"9","author":"S\u00e1ez-De la Fuente","year":"2007","journal-title":"Atenci\u00f3n Farmac\u00e9utica"},{"key":"10.1016\/j.farma.2023.06.007_bb0110","first-page":"e1127","article-title":"Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: a quantitative market research-based survey","volume":"1","author":"Aapro","year":"2018","journal-title":"Cancer Rep"},{"key":"10.1016\/j.farma.2023.06.007_bb0115","first-page":"141","article-title":"Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting","volume":"20","author":"Burmesteir","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.farma.2023.06.007_bb0120","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1200\/JOP.2012.000816","article-title":"Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study","volume":"10","author":"Gilmore","year":"2014","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.farma.2023.06.007_bb0125","first-page":"201","article-title":"A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre","volume":"16","author":"Molassiotis","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.farma.2023.06.007_bb0130","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/annonc\/mdx698","article-title":"A randomized Phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving","volume":"29","author":"Zhang","year":"2018","journal-title":"Ann Oncol"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634323000739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634323000739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:18:18Z","timestamp":1761106698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634323000739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1130634323000739"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2023.06.007","relation":{},"ISSN":["1130-6343"],"issn-type":[{"type":"print","value":"1130-6343"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Have changes concerning carboplatin and anthracyclines been incorporated?","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2023.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2023.04.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}